These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24602462)

  • 1. Novel therapies for diabetic kidney disease.
    Alicic RZ; Tuttle KR
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):121-33. PubMed ID: 24602462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New potential agents in treating diabetic kidney disease: the fourth act.
    Williams ME
    Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The next generation of diabetic nephropathy therapies: an update.
    Williams ME; Tuttle KR
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):212-22. PubMed ID: 15822057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.
    Harlan SM; Heinz-Taheny KM; Sullivan JM; Wei T; Baker HE; Jaqua DL; Qi Z; Cramer MS; Shiyanova TL; Breyer MD; Heuer JG
    J Am Soc Nephrol; 2018 Feb; 29(2):477-491. PubMed ID: 29061652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diabetic nephropathy: emerging treatments].
    Gueutin V; Gauthier M; Cazenave M; Izzedine H
    Nephrol Ther; 2014 Jul; 10(4):210-5. PubMed ID: 24938412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic kidney disease: a report from an ADA Consensus Conference.
    Tuttle KR; Bakris GL; Bilous RW; Chiang JL; de Boer IH; Goldstein-Fuchs J; Hirsch IB; Kalantar-Zadeh K; Narva AS; Navaneethan SD; Neumiller JJ; Patel UD; Ratner RE; Whaley-Connell AT; Molitch ME
    Am J Kidney Dis; 2014 Oct; 64(4):510-33. PubMed ID: 25257325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
    Yubero-Serrano EM; Woodward M; Poretsky L; Vlassara H; Striker GE;
    Clin J Am Soc Nephrol; 2015 May; 10(5):759-66. PubMed ID: 25710801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
    Tuttle KR; Anderson PW
    Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and Management of Type 2 Diabetic Kidney Disease.
    Doshi SM; Friedman AN
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1366-1373. PubMed ID: 28280116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
    Ishikawa N; Miyata T; Kurokawa K
    Nihon Rinsho; 2004 May; 62 Suppl 5():389-92. PubMed ID: 15197951
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetic kidney disease: a report from an ADA Consensus Conference.
    Tuttle KR; Bakris GL; Bilous RW; Chiang JL; de Boer IH; Goldstein-Fuchs J; Hirsch IB; Kalantar-Zadeh K; Narva AS; Navaneethan SD; Neumiller JJ; Patel UD; Ratner RE; Whaley-Connell AT; Molitch ME
    Diabetes Care; 2014 Oct; 37(10):2864-83. PubMed ID: 25249672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.
    Adler SG; Schwartz S; Williams ME; Arauz-Pacheco C; Bolton WK; Lee T; Li D; Neff TB; Urquilla PR; Sewell KL
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1420-8. PubMed ID: 20522536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
    Gilbert RE; Kim SA; Tuttle KR; Bakris GL; Toto RD; McGill JB; Haney DJ; Kelly DJ; Anderson PW
    Diabetes Care; 2007 Apr; 30(4):995-6. PubMed ID: 17229944
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel therapies of diabetic nephropathy.
    Burney BO; Kalaitzidis RG; Bakris GL
    Curr Opin Nephrol Hypertens; 2009 Mar; 18(2):107-11. PubMed ID: 19434047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase C-beta inhibition for diabetic kidney disease.
    Tuttle KR
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
    Williams ME
    Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing management of diabetic nephropathy.
    Dunfee TP
    Hosp Pract (1995); 1995 May; 30(5):45-9, 53-5. PubMed ID: 7744980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.